Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (6 thèses dirigées)
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Visual neglect in posterior cortical atrophy : a new methodological approach for a better understanding of the neglect syndrome
2012Doctorant·e : Katia Santos Andrade
Contribution à l'étude des fonctions cognitives préfrontales médianes et orbitales chez l'homme
2012Doctorant·e : Maxime Bertoux
La maladie d'Alzheimer : du diagnostic phénotypique au diagnostic étiologique
2011Doctorant·e : Leonardo Cruz de Souza
L' apathie dans la maladie de Parkinson : mécanismes physiopathologiques et fonctionnels
2006Doctorant·e : Virginie Czernecki
Cortex préfrontal et contrôle de l'action : approche clinique et expérimentale
2003Doctorant·e : Andrea Slachevsky-Chonchol
Réactions différées et système striato-frontal chez l'homme
1996Doctorant·e : Marc Vérin
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
119
119 articles ont été cités au moins 119fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
82 748
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
866
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
422
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre National de la Recherche Scientifique · Centre National de la Recherche Scientifique · Inserm
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
L’activité de l’Association internationale pour la protection légale des travailleurs au prisme des archives de son bureau exécutif (1901-1914)
2026Chapitre
Uma justiça ideal? A conciliação do contencioso profissional no século XIX
2026Chapitre
Les naissances du droit social international, 1889-1918
2026Ouvrage
Detection of triboelectric discharges during dust events on Mars
2025ArticleNature
Prediction-powered Inference for Clinical Trials: application to linear covariate adjustment
2025ArticleBMC Medical Research Methodology
Educational attainment, electroencephalographic rhythms, cortical structure, and cognitive performance over 2 years in older adults with subjective memory complaints and brain amyloidosis
2025ArticleAlzheimer's & Dementia : the Journal of the Alzheimer's Association
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC
2025ArticleAlzheimer's Research and Therapy
Search for in situ signatures of electric activity on Mars
2025CongrèsEGU General Assembly 2025
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP SUN SITE PITIE SALPETRIERE
47-83 47 BD DE L HOPITAL, 75651 PARIS CEDEX 13
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
JAMA neurology · 2024
ImportanceSince 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer’s Association (AA) criteria for AD furthers this direction. However, concerns about a purely biological definition of AD being applied clinically, the understanding of AD by society at large, and the translation of blood-based biomarkers into clinical practice prompt these International Working Group (IWG) updated recommendations.ObjectiveTo consider the revised AA criteria and to offer an alternative definitional view of AD as a clinical-biological construct for clinical use. The recommendations of the 2021 IWG diagnostic criteria are updated for further elaborating at-risk and presymptomatic states.Evidence ReviewPubMed was searched for articles published between July 1, 2020, and March 1, 2024, using the terms “biomarker” OR “amyloid” OR “tau” OR “neurodegeneration” OR “preclinical” OR “CSF” OR “PET” OR “plasma” AND “Alzheimer’s disease.” The references of relevant articles were also searched.FindingsIn the new AA diagnostic criteria, AD can be defined clinically as encompassing cognitively normal people having a core 1 AD biomarker. However, recent literature shows that the majority of biomarker-positive cognitively normal individuals will not become symptomatic along a proximate timeline. In the clinical setting, disclosing a diagnosis of AD to cognitively normal people with only core 1 AD biomarkers represents the most problematic implication of a purely biological definition of the disease.Conclusions and RelevanceThe ultimate aim of the field was to foster effective AD treatments, including preventing symptoms and dementia. The approach of diagnosing AD without a clinical and biological construct would be unwarranted and potentially concerning without a clear knowledge of when or whether symptoms will ever develop. It is recommended that those who are amyloid-positive only and, more generally, most biomarker-positive cognitively normal individuals, should not be labeled as having AD. Rather, they should be considered as being at risk for AD. The expansion of presymptomatic AD is viewed as a better diagnostic construct for those with a specific pattern of biomarkers, indicating that they are proximate to the expression of symptoms in the near future.
Alzheimer's research & therapy · 2023
Abstract Background Development of in vivo biomarkers has shifted the diagnosis of Alzheimer’s disease (AD) from the later dementia stages of disease towards the earlier stages and has introduced the potential for pre-symptomatic diagnosis. The International Working Group recommends that AD diagnosis is restricted in the clinical setting to people with specific AD phenotypes and supportive biomarker findings. Main body In this review, we discuss the phenotypic presentation and use of biomarkers for the early diagnosis of typical and atypical AD and describe how this can support clinical decision making, benefit patient communication, and improve the patient journey. Early diagnosis is essential to optimize the benefits of available and emerging treatments. As atypical presentations of AD often mimic other dementias, differential diagnosis can be challenging and can be facilitated using AD biomarkers. However, AD biomarkers alone are not sufficient to confidently diagnose AD or predict disease progression and should be supplementary to clinical assessment to help inform the diagnosis of AD. Conclusions Use of AD biomarkers with incorporation of atypical AD phenotypes into diagnostic criteria will allow earlier diagnosis of patients with atypical clinical presentations that otherwise would have been misdiagnosed and treated inappropriately. Early diagnosis is essential to guide informed discussion, appropriate care and support, and individualized treatment. It is hoped that disease-modifying treatments will impact the underlying AD pathology; thus, determining the patient’s AD phenotype will be a critical factor in guiding the therapeutic approach and the assessment of the effects of interventions.
The Lancet regional health. Europe · 2023
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Nature · 2025 · Journal Article
Chide B, Lorenz RD, Montmessin F, Maurice S, et al.
Nature aging · 2025 · Journal Article
Feldman HH, Villain N, Frisoni GB, Dubois B
Lancet (London, England) · 2025 · Journal Article
Frisoni GB, Aho E, Brayne C, Ciccarelli O, et al.
Lancet (London, England) · 2025 · Journal Article
Frisoni GB, Hansson O, Nichols E, Garibotto V, et al.
BMC medical research methodology · 2025 · Journal Article
Poulet PE, Tran M, Tezenas du Montcel S, Dubois B, et al.
medRxiv : the preprint server for health sciences · 2025 · Journal Article
Poulet PE, Tran M, Tezenas du Montcel S, Dubois B, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025 · Journal Article
Lopez S, Hampel H, Percio CD, Noce G, et al.
The Lancet. Neurology · 2025 · Letter
Villain N, Frisoni GB, Feldman HH, Dubois B
JAMA neurology · 2025 · Journal Article
Dubois B, Villain N, Feldman HH
Alzheimer's research & therapy · 2025 · Journal Article
Frederiksen KS, Boada M, Dubois B, Engelborghs S, et al.
The journal of prevention of Alzheimer's disease · 2025 · Journal Article
Frisoni GB, Ribaldi F, Allali G, Bieth T, et al.
JAMA psychiatry · 2025 · Journal Article
Wiels WA, Oomens JE, Engelborghs S, Baeken C, et al.
BMJ neurology open · 2025 · Journal Article
Cabreira V, Alty J, Antic S, Araujo R, et al.
Neuro-degenerative diseases · 2025 · Letter
Salvioni Chiabotti P, Salvioni Chiabotti P, Bommarito G, Michel P, et al.
European journal of neurology · 2025 · Journal Article
Cabreira V, Alty J, Antic S, Araújo R, et al.
Journal of neurology · 2024 · Journal Article
Raposo Pereira F, Chaumon M, Dubois B, Bakardjian H, et al.
Frontiers in aging neuroscience · 2024 · Journal Article
Raposo Pereira F, George N, Dalla Barba G, Dubois B, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024 · Journal Article
Bollack A, Collij LE, García DV, Shekari M, et al.
Neurobiology of aging · 2024 · Journal Article
Lopez S, Hampel H, Chiesa PA, Del Percio C, et al.
Journal of Alzheimer's disease : JAD · 2024 · Journal Article
Rapos Pereira F, George N, Dalla Barba G, Dubois B, et al.
Frontiers in neurology · 2023 · Journal Article
Andrade K, Guieysse T, Medani T, Koechlin E, et al.
Alzheimer's research & therapy · 2023 · Observational Study
Bader I, Bader I, Lopes Alves I, Vállez García D, et al.
Alzheimer's research & therapy · 2023 · Published Erratum
Diaz-Galvan P, Lorenzon G, Mohanty R, Mårtensson G, et al.
Alzheimer's research & therapy · 2023 · Journal Article
Dubois B, von Arnim CAF, Burnie N, Bozeat S, et al.
Alzheimer's research & therapy · 2023 · Randomized Controlled Trial
Diaz-Galvan P, Lorenzon G, Mohanty R, Mårtensson G, et al.
Neurobiology of disease · 2023 · Journal Article
Khrouf W, Saracino D, Rucheton B, Houot M, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023 · Multicenter Study
Lespinasse J, Chêne G, Mangin JF, Dubois B, et al.
Alzheimer's research & therapy · 2023 · Journal Article
Lesoil C, Bombois S, Guinebretiere O, Houot M, et al.
The Lancet regional health. Europe · 2023 · Journal Article
Frisoni GB, Altomare D, Ribaldi F, Villain N, et al.
Neurology · 2023 · Journal Article
Planche V, Bouteloup V, Pellegrin I, Mangin JF, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022 · Journal Article
Janssen O, Jansen WJ, Vos SJB, Boada M, et al.
Neurology · 2022 · Journal Article
Xicota L, Gyorgy B, Grenier-Boley B, Lecoeur A, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022 · Letter
Dodich A, Boccardi M, Sacco L, Monsch AU, et al.
Alzheimer's research & therapy · 2022 · Journal Article
Grasset L, Proust-Lima C, Mangin JF, Habert MO, et al.
Brain communications · 2022 · Journal Article
Morin A, Funkiewiez A, Routier A, Le Bouc R, et al.
Journal of Alzheimer's disease : JAD · 2025 · Clinical Trial, Phase II
Haaland B, Dickson SP, Santana AF, Tanzi RE, et al.
The Lancet. Neurology · 2025 · Journal Article
Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, et al.
Neurology · 2024 · Journal Article
Bouteloup V, Pellegrin I, Dubois B, Chene G, et al.
The Lancet. Neurology · 2024 · Journal Article
Frisoni GB, Festari C, Massa F, Cotta Ramusino M, et al.
The Lancet. Neurology · 2025 · Journal Article
Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, et al.
medRxiv : the preprint server for health sciences · 2025 · Journal Article
Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, et al.
JAMA neurology · 2024 · Journal Article
Dubois B, Villain N, Schneider L, Fox N, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023 · Systematic Review
Festari C, Massa F, Cotta Ramusino M, Gandolfo F, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023 · Journal Article
Grasset L, Planche V, Bouteloup V, Azouani C, et al.
Alzheimer's research & therapy · 2022 · Published Erratum
Sakr FA, Grothe MJ, Cavedo E, Jelistratova I, et al.
Journal of integrative neuroscience · 2024 · Randomized Controlled Trial
Andrade K, Houmani N, Guieysse T, Razafimahatratra S, et al.
Journal of Alzheimer's disease : JAD · 2025 · Journal Article
Mukesha D, Sarter M, Dubray M, Durand F, et al.
BMJ open ophthalmology · 2026 · Journal Article
Lepoittevin M, Greig J, Erol O, Benani A, et al.
BMJ open ophthalmology · 2026 · Journal Article
Lepoittevin M, Greig J, Erol O, Benani A, et al.
Testing the therapeutic effects of transcranial direct current stimulation (tDCS) in semantic dementia: a double blind, sham controlled, randomized clinical trial
Abstract Background Semantic dementia is a neurodegenerative disease that primarily affects the left anterior temporal lobe, resulting in a gradual loss of conceptual knowledge. There is currently no validated treatment.
Sundqvist et al. - The white matter module-hub network of semantics revealed by semantic dementia - Supplementary Figure
<strong>Supplementary Figure</strong> The correlation circle: correlations between the different MRI measures and semantic scores and the two first principal components via coordinates. The two first components sum up 68
Sundqvist et al. - The white matter module-hub network of semantics revealed by semantic dementia - CAPP Study Group
<strong>CAPP Study Group</strong> Link to publication: https://doi.org/10.1162/jocn_a_01549
The meta-memory ratio: a new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer’s disease
Abstract Background Lack of awareness of cognitive decline (ACD) has been described at the preclinical and prodromal stages of Alzheimer’s disease (AD). In this study, we introduced a meta-memory ratio (MMR) and explored
Un code pour la Nation. La codification du droit pénal au XIXe siècle (France, Belgique, Angleterre)
Le présent ouvrage est issu d’un rapport de recherche financé par le G. I. P. « Mission Droit et Justice » en juillet 2000. Initiée et dirigée par Renée Martinage, Professeur émérite à l’Université Lille 2, la recherche
Explaining the association between social and lifestyle factors and cognitive functions: a pathway analysis in the Memento cohort
Abstract Background This work aimed to investigate the potential pathways involved in the association between social and lifestyle factors, biomarkers of Alzheimer’s disease and related dementia (ADRD), and cognition. Me
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
medRxiv : the preprint server for health sciences · 2025 · Journal Article
Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, et al.
European journal of nuclear medicine and molecular imaging · 2023 · Clinical Trial, Phase III
Chen CD, McCullough A, Gordon B, Joseph-Mathurin N, et al.
Alzheimer's research & therapy · 2023 · Published Erratum
Dubois B, López-Arrieta J, Lipschitz S, Doskas T, et al.
Alzheimer's research & therapy · 2023 · Randomized Controlled Trial
Dubois B, López-Arrieta J, Lipschitz S, Doskas T, et al.